At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 16, 2026 at 07:00 ET
Structure Therapeutics announced positive Phase 2 results for aleniglipron, an oral GLP-1 receptor agonist, showing placebo-adjusted weight loss of up to 16.3% (39 lbs) at 44 weeks, the highest reported efficacy among oral GLP-1RAs and comparable to injectable versions. The data support advancement into Phase 3 trials, with an FDA end-of-Phase 2 meeting scheduled for Q2 2026 and trial initiation expected in H2 2026.
- Aleniglipron achieved placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks in the ACCESS II study (p<0.0001).
- In the open-label extension, weight loss reached up to 16.2% (40.5 lbs) at 56 weeks with no evidence of plateau.
- Low discontinuation rates (2.0–3.4%) due to adverse events with the 2.5 mg starting dose support improved tolerability.
- Phase 3 initiation remains on track for second half of 2026, following an FDA End-of-Phase 2 meeting in Q2 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access